MedTrace Logo

Laryngeal Mask Airway (LMA) Insertion With Sevoflurane and Remifentanil

NCT01456299 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2019-03-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to determine the most suitable effect-site concentration of remifentanil for the LMA insertion during inhaled induction with 8% sevoflurane in adults.

Conditions

  • Laryngismus

Interventions

DRUG

Remifentanil 1

"Remifentanil 1": "The R1 group, which received a target effect-site remifentanil concentration of 1 ng/ml.

DRUG

Control

The control group, which received an infusion of normal saline

DRUG

Remifentanil 2

"Remifentanil 2": "The R2group, which received a target effect-site remifentanil concentration of 2 ng/ml.

Sponsors & Collaborators

  • Gachon University Gil Medical Center

    lead OTHER

Principal Investigators

  • Jong Yeop Kim, MD,PhD · Ajou University School of Medicine

  • Jong Yeop Kim, MD, PhD · Ajou Universiy School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01456299 on ClinicalTrials.gov